Amazon Secures 200 MW Wind Power Deals in Sweden 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Asian Stocks Slip as Fed Rate Hike Bets and Oil Surge Weigh 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Oil Prices Rise as US-Iran Conflict Threatens Middle East Supply 
Treasury Yields Set to Stay High as Debt Supply Pressures Bond Market 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Global Markets Brace for Fed Rate Hike as Oil Tops $91 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Ukraine Sanctions Chief Heads to Washington to Push Russia Bill 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Add as a preferred source on Google
Bristol Myers and AbbVie are reportedly planning to terminate some of their staff in California. The job cuts will be the latest in a string of layoffs in the biopharma industry in the United States.
As per Reuters, a combined total of 360 job roles are set to be affected by the plan. Both Bristol Myers Squibb Co, and AbbVie Inc. reportedly informed the officials of the California administration that they will eliminate some of their employees.
The notices were said to have been filed last week with the state but were only made public a few days after. In the filing, Bristol Myers Squibb indicated that it will remove up to 261 jobs in its offices in two locations in San Diego, California. As of AbbVie, it told the state it will be slashing some 99 jobs in Irvine.
The company’s spokesman said that the layoffs at Bristol Myers are taking place after the company acquired Turning Point Therapeutics Inc. for $4.1 billion. The biopharma’s acquisition deal with the San Diego-based biotech drug developer closed just last month.
Fierce Pharma reported that the job cut notices were separately filed by Bristol Myers and AbbVie under the Worker Adjustment and Retraining Notification (WARN) alerts. The filing is to officially inform California that there will be layoffs from their companies this November.
With the move, Bristol Myers and AbbVie have joined other major biopharmaceutical firms such as Novartis and Biogen in the reduction of their workforce. At any rate, BMS’s job cuts are related to its latest acquisition deal of Turning Point Therapeutics and this was confirmed by the company through its spokesman.
“We are very pleased to have completed the acquisition of Turning Point Therapeutics to further strengthen our leading oncology franchise,” the company said in a separate statement. “As part of the integration, all incoming employees received retention packages tied to continued service to BMS for a period of time and have been encouraged to apply to long-term roles at BMS after their retention period ends.”
Meanwhile, AbbVie was not able to respond immediately to a request for comment regarding the job cuts.
